

# ANGLE PLC

17:30 25 Jun 2020

## ANGLE hails major progress, targets regulator submissions in third quarter of 2020

ANGLE PLC (LON:AGL) has hailed "major progress" in its latest results as it targeted regulatory submission for its Parsortix system to the US Food and Drug Administration (FDA) in the third quarter of 2020.

Parsortix is designed to capture and harvest circulating tumour cells from metastatic breast cancer patients.

### WATCH: ANGLE PLC's Andrew Newland updates as blood donations restart to support its key studies

In an outlook statement accompanying results for the eight months ended December 31, 2019, the liquid biopsy specialist said its full De Novo FDA submission is in preparation so that it can be "rapidly submitted" once the remaining analytical samples needed to meet requirements identified in a meeting in January were available and analysed.

While the samples had been delayed by restrictions during the coronavirus pandemic, which had prevented the recruitment of volunteer blood donors, ANGLE said work was back in progress and the FDA submission was expected in the third quarter of the year.

The company added that it is also making progress with its ovarian cancer test, with patient enrolment expected to complete by the end of 2020 with the aim of supporting a laboratory-developed test for ovarian cancer in the new year.

In its figures for the eight months, following a change in the company's accounting reference date to December 31 from April 30, ANGLE reported a pre-tax loss of £7.7m compared to a £10.9m loss for the year ended April 30, 2019, while revenues were £581,000 compared to £678,000 in the comparative period.

ANGLE also reported it had raised gross proceeds of £18m during the year from institutional investors, including new "significant" backers in the US, and as such had ended the year with a cash balance of £18.8m.

"During the period, we raised further growth capital, expanding our existing UK shareholder base and adding key new US investors. ANGLE has a robust balance sheet with sufficient working capital and liquidity. We remain confident about the Group's long-term prospects", said ANGLE's non-executive chairman Garth Selvey.

Shares in ANGLE were 0.8% lower at 59p in early deals on Thursday.

**Price:** 40.65

**Market Cap:** £87.56 m

### 1 Year Share Price Graph



### Share Information

**Code:** AGL

**Listing:** AIM

**52 week High Low**  
77.9999 40

**Sector:** Pharma & Biotech

**Website:** www.angleplc.com

### Company Synopsis:

ANGLE PLC develops products for use in rare cell diagnostics that enable early, accurate identification of an individual's condition for the prevention, treatment, and monitoring of disease.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).